Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): Baseline characteristics, treatment history and disease burden

Abstract

Moderate to severe atopic dermatitis (AD) has a high disease burden and a significant effect on quality of life. Observational studies are necessary to determine the patient disease burden and long-term disease control in the Japanese population. ADDRESS-J is a non-interventional, observational registry of adult Japanese patients with moderate to severe AD. Herein, we report baseline data from the ADDRESS-J study describing disease characteristics and current treatment practices. At baseline, 300 adult AD patients with Investigator's Global Assessment (IGA) scores (range, 0-4) of 3 (moderate) or 4 (severe) whose treatments for AD were intensified, were assessed for clinical and patient-reported outcomes and current AD treatments. The registry patients' median age was 34.0 years; 60.7% were male and 71.7% had had AD for more than 20 years. At baseline, 220 study patients had an IGA score of 3 and 80 had an IGA score of 4. The median Eczema Area and Severity Index score was 21.7 (range, 0-72), the median body surface area involvement was 46.25%, and the median pruritus numerical rating scale score was 7.0 (range, 0-10); for each of these measures, higher scores represent greater severity. Most registry patients (86.7%) had recently used topical corticosteroids or topical calcineurin inhibitors as treatment for AD. This registry cohort represents a population of Japanese patients with moderate to severe AD and provides an important resource for characterizing the disease burden and evaluating the safety and effectiveness of various AD treatments.

Keywords: Japan; adult; atopic dermatitis; burden of disease; registry.

Figure 1

ADDRESS‐J registry study design. AD, atopic dermatitis; D, day; M, month.

Figure 2

Association of prurigo and pruritus NRS. (a) Pruritus NRS scores plotted for patients with and without prurigo nodules at baseline. (b) Pruritus NRS scores plotted for patients with prurigo nodules by number category and (c) by maximal size category. Number of patients in each category are shown as n. Bars depict mean ± standard deviation. NRS, numerical rating scale.

Figure 3

Association of IGA score and other disease measures, including patient‐reported outcomes. (a–g) Bars depict median with interquartile values (Q1, Q3), and black and red dots depict the patients with an IGA of 3 and 4, respectively. BSA, body surface area; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; EQ‐5D, EuroQOL group health questionnaire with five dimensions; IGA, Investigator's Global Assessment; NRS, numerical rating scale; POEM, Patient‐Oriented Eczema Measure; VAS, visual analog scale.

Figure 4

Relationship between various disease measures and disease severity. Correlations between disease severity measures are shown in a matrix. The values in the graphs are Spearman's rank correlation coefficient (r). Black and red symbols depict the patients with an IGA of 3 and 4, respectively. BSA, body surface area; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; EQ‐5D, EuroQOL group health questionnaire with five dimensions; IGA, Investigator's Global Assessment; NRS, numerical rating scale; POEM, Patient‐Oriented Eczema Measure; VAS, visual analog scale.